ImmunityBio, Inc.
10-K
February 23, 2026
Key Highlights
- Significant revenue growth in 2025, primarily driven by the initial commercializ...
- Successful market entry and initial adoption of ANKTIVA® for BCG-unresponsive NM...
- Broad pipeline of cell and gene therapies leveraging the NANT Cancer Vaccine pla...
Read Analysis
🤖 AI Generated